Biotech funds began their rebound last week as positive trial data and merger and acquisition news revived the sector. The ARK Genomic Revolution ETF (ARKG) rallied 7.15% over one week, ahead of all other ETFs in the health and biotech equities ETFs category, according to VettaFi. The actively...